-48%

est. 2Y upside i

Healthcare

Rank

#3674

Sector

Healthcare Technology

Est. Liquidity

~2Y

Data Quality

Data: Medium

Current equity upside is deeply negative (-48% expected) due to a 66% discount in secondary market, near-zero growth, and fierce incumbent competition.

Last updated: July 3, 2026

Bull (5%)+42%

If Thoreau roll-up accelerates multiple to 8x and IPO window opens, common stock yields 42.4% upside after 20% dilution.

Base (40%)-26%

Multiple converges to 5x in line with public comps; common stock declines 6.3% before dilution, net -26.3% after 20% dilution.

Bear (55%)-72%

Multiple compresses to 3x due to crushing incumbent competition; common stock after preference and dilution yields -72.1%.

Est. time to liquidity~2.0 years

Preference Stack Risk

high

Funding Intensity

21%

Total funding $71M vs entry valuation $341.85M; preferred liquidation preference overhang is 20.8% of common value.

Dilution Risk

high

With low growth and no profitability, a capital raise within 2 years is probable, diluting common by ~20%.

Secondary Liquidity

limited

Secondary market trades at $341.85M, 66% below primary round, indicating limited liquidity for employees.

Other — 34 roles

View all 34 open roles at SmarterDx →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on SmarterDx's data — designed to show you've done your homework.

  • 1

    “How does SmarterDx plan to accelerate growth given only 5% YoY revenue growth?”

  • 2

    “What is the timeline for the reported Thoreau roll-up and how does it affect employee equity?”

  • 3

    “How does the company compete against Optum and Nuance for hospital contracts?”

Community

Valuation Sentiment

Our model estimates -48% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.